Skip to main content

Table 1 Patient’s neo-epitopes to which T cell reactivity was detected.

From: Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4

Patient% Tumor# Mut# SLP# SSPGenesMut cDNAMut a.a.% Mut (WES)PeptidePeptide ID
NIC321212447PARVAc.328C>Gp.P110R11NLPLSPIPFELDREDTMLEENEVRTL01
     G3BP1c.244G>Ap.A82T11NCHTKIRHVDAHTTLNDGVVVQVMGL13
     G3BP1c.244G>Ap.A82T11IRHVDAHTTLS13-1
NIC448303946ACTR10c.638G>Ap.R213H15SVPEGVLEDIKAHTCFVSDLKRGLKL06
     RAE1c.1106A>Gp.X369W13WWLETLAQPELFLSTLPHLCTNLGPL20-2
     PDP1c.1024C>Tp.R342W45PKSEAKSVVKQDWLLGLLMPFRAFGL29
     PDP1c.1024C>Tp.R342W45SEAKSVVKQDWS29-1
     PDP1c.1024C>Tp.R342W45SEAKSVVKQDWLS29-2
NIC572497194
NIC679232432
NIC778334470
NIC15431515108QRICH1c.1054C>Ap.V352F14VHVSGSPTALAAFKLEDDKEKMVGTL11
NIC1751454760
  1. % Tumor tumor purity, Mut mutation, SLP synthetic long peptides, SSP synthetic short peptides, WES reads in whole-exome sequencing.